Probiotics and Diarrhoea Management in Enterally TubeFed Critically Ill Patients

1. Introduction

Enteral nutrition (EN) is the preferred route for delivering nutrients to critically ill patients who cannot maintain adequate oral intake. While EN supports gut integrity, it is frequently accompanied by gastrointestinal (GI) complications, the most common of which is diarrhoea. Diarrhoea in the intensivecare setting influences fluid balance, electrolyte status, nutritional delivery, and overall patient outcomes.

In recent years, probiotic supplementation has emerged as a potential adjunctive strategy to reduce the incidence and severity of ENassociated diarrhoea. This page reviews the pathophysiology of diarrhoea in tubefed patients, the rationale for probiotic use, evidence from clinical trials, and practical recommendations for bedside implementation.

2. Causes of Diarrhoea in Enterally Fed Patients

Diarrhoea in the critically ill is usually multifactorial. The main contributors are:

• Formularelated factors: hyperosmolar feeds, rapid infusion rates, or intolerance to certain macronutrients (e.g., lactose).
• Medicationinduced: antibiotics, prokinetics, and medications that alter motility.
• Gut dysbiosis: loss of commensal bacteria due to critical illness, broadspectrum antibiotics, and impaired immunity.
• Infection: Clostridioides difficile, norovirus, or other pathogens.
• Physiologic alterations: reduced splanchnic perfusion, impaired motility, and impaired absorption due to mucosal injury.

3. Probiotics Definitions & Mechanisms

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. The most studied genera in the ICU are Lactobacillus, Bifidobacterium, and Saccharomyces boulardii. Their proposed mechanisms relevant to diarrhoea include:

1. Restoration of microbial balance (colonisation resistance).
2. Production of shortchain fatty acids that improve colonic absorption of water and electrolytes.
3. Competitive inhibition of pathogenic bacteria.
4. Modulation of the immune response and reduction of inflammatory cytokines.
5. Enhancement of gut barrier function.

4. Evidence from Clinical Trials

Several randomized controlled trials (RCTs) and metaanalyses have examined probiotic use in tubefed ICU patients. The table below summarises key findings.

Overall, the evidence suggests a modest but consistent reduction in diarrhoea incidence when probiotics are administered alongside EN, especially in patients receiving antibiotics.

5. Practical Recommendations

5.1 Patient Selection

• Critically ill adults on continuous or bolus EN for 48h.
• Receiving or anticipated to receive broadspectrum antibiotics.
• Without contraindications (see 5.3).

5.2 Choosing a Probiotic

Prefer products with documented strainspecific efficacy and a viable count 10CFU per dose. Multistrain preparations may provide broader coverage.

5.3 Contraindications & Safety

• Severe immunosuppression (e.g., neutropenia <500/L, chemotherapy within 2weeks).
• Critical intestinal barrier disruption (e.g., necrotising enterocolitis, uncontrolled GI perforation).
• Known allergy to probiotic capsule ingredients.
• Use of Saccharomyces boulardii together with systemic antifungals may reduce efficacy.

5.4 Administration

1. Reconstitute freezedried powders in sterile water or compatible enteral formula as per manufacturer.
2. Deliver via the feeding tube 30minutes before the next EN bolus to minimise interaction.
3. Document the exact strain, CFU dose, and timing in the medication chart.

5.5 Monitoring

• Daily stool frequency and consistency (Bristol Stool Chart).
• Electrolytes, fluid balance, and signs of systemic infection.
• If diarrhoea persists >5days, reassess feed concentration, rate, and consider stool cultures.

6. Integration with Other DiarrhoeaControl Strategies

Probiotic therapy should be part of a multimodal approach:

• Feed optimisation: start with lowosmolality formulas, titrate infusion rate, and consider fibreenriched or peptidebased feeds if intolerance persists.
• Antibiotic stewardship: limit unnecessary antibiotics and use narrowspectrum agents when possible.
• Pharmacologic adjuncts: loperamide or racecadotril for symptomatic control when not contraindicated.
• Infection control: strict hand hygiene and isolation precautions for C.difficile.

7. Future Directions

Research gaps remain:

1. Optimal strain combinations and dosing regimens for the critically ill.
2. Longterm safety in patients with high severity scores (APACHEII>25).
3. Impact of probiotic use on microbiome recovery postICU discharge.

Ongoing multicentre RCTs are evaluating nextgeneration, genomesequenced probiotics that may provide targeted metabolic benefits.

8. Key Takeaways

• Enteraltubefed critically ill patients frequently develop diarrhoea, which hampers nutritional goals.
• Probiotics, particularly Lactobacillus and Bifidobacteriumbased preparations, modestly reduce the incidence and duration of diarrhoea.
• Selection of appropriate strains, dose (10CFU), and timing is essential; contraindications must be screened.
• Probiotic therapy should complement, not replace, optimisation of feed composition, rate, and antibiotic stewardship.